Lycoflavon

**Lycoflavon** is a Lycotec-developed oral small-molecule combinatory product in which **genistein and daidzein isoflavones** are embedded into **trans-lycopene** clusters using the company's lycosome-style delivery approach. According to Lycotec, the isoflavone components are intended to increase insulin receptor expression, while trans-lycopene is described as an acid-resistant carrier that protects the payload in the stomach and may also contribute anti-hypoxia and microcirculatory effects in steatotic liver, pancreas, and skeletal muscle tissue. The program is being developed for **insulin resistance** and is listed by Lycotec as a **Phase 2** asset, but the precise molecular target profile and clinically validated mechanism remain incompletely disclosed in public company materials.

Other names

genistein + daidzein isoflavones embedded into trans-lycopeneGDI embedded into trans-lycopene